Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer ...

As global markets grapple with inflation concerns and trade policy uncertainties, investors are seeking opportunities that can navigate these challenges. Penny stocks, a term that may seem outdated, ...

The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme.

The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule ...

First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC. IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy. Projected cash runway extends ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...

Sutro Biopharma, Inc.’s STRO share price has surged by 15.10%, which has investors questioning if this is right time to sell.

The results were presented in a poster entitled "Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload" at the 36th EORTC-NCI-AACR ...

First patient dosed in Phase 1 clinical trial evaluating IM-1021, a ROR1-targeted ADC. IND submitted in March 2025 for IM-3050, a FAP-targeted radioligand therapy. Projected cash runway extends into ...

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancer cases and remains one of the leading causes of cancer-related mortality worldwide. The high mortality rate is ...